IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma | Oncogene – Nature.com

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Oncogene volume 41, pages 600–611 (2022)Cite this article
1452 Accesses
9 Citations
12 Altmetric
Metrics details
A Correction to this article was published on 09 February 2023
This article has been updated
As the p53 tumor suppressor is rarely mutated in conjunctival melanoma (CM), we investigated its activation as a potential therapeutic strategy. Preventing p53/Mdm2 interaction by Nutlin-3, the prototypical Mdm2 antagonist, or via direct siRNA Mdm2 depletion, increased p53 and inhibited viability in CM cell lines. The sensitivity to Nutlin-3 p53 reactivation with concomitant Mdm2 stabilization was higher than that achieved by siRNA, indicative of effects on alternative Mdm2 targets, identified as the cancer-protective IGF-1R. Nutlin-3 treatment increased the association between IGF-1R and β-arrestin1, the adaptor protein that brings Mdm2 to the IGF-1R, initiating receptor degradation in a ligand-dependent manner. Controlled expression of β-arrestin1 augmented inhibitory Nutlin-3 effects on CM survival through enhanced IGF-1R degradation. Yet, the effect of IGF-1R downregulation on cell proliferation is balanced by β-arrestin1-induced p53 inhibition. As mitomycin (MMC) is a well-established adjuvant treatment for CM, and it triggers p53 activation through genotoxic stress, we evaluated how these alternative p53-targeting strategies alter the cancer-relevant bioactivities of CM. In 2D and 3D in vitro models, Nutlin-3 or MMC alone, or in combination, reduces the overall cell tumor growth ~30%, with double treatment inhibition rate only marginally higher than single-drug regimens. However, histopathological evaluation of the 3D models revealed that Nutlin-3 was the most effective, causing necrotic areas inside spheroids and complete loss of nuclear staining for the proliferative marker Ki67. These findings were further validated in vivo; zebrafish xenografts demonstrate that Nutlin-3 alone has higher efficacy in restraining CM tumor cell growth and preventing metastasis. Combined, these results reveal that β-arrestin1 directs Mdm2 toward different substrates, thus balancing IGF-1R pro-tumorigenic and p53-tumor suppressive signals. This study defines a potent dual-hit strategy: simultaneous control of a tumor-promoter (IGF-1R) and tumor-suppressor (p53), which ultimately mitigates recurrent and metastatic potential, thus opening up targeted therapy to CM.
This is a preview of subscription content, access via your institution

Subscribe to this journal
Receive 50 print issues and online access
£169.00 per year
only £3.38 per issue

Rent or buy this article
Prices vary by article type
from$1.95
to$39.95

Prices may be subject to local taxes which are calculated during checkout
All data associated with this study are present in the paper or the Supplementary material.
A Correction to this paper has been published: https://doi.org/10.1038/s41388-023-02607-8
Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. Photochem Photobiol. 2008;84:539–49.
Article  CAS  PubMed  PubMed Central  Google Scholar 
Wood JM, Jimbow K, Boissy RE, Slominski A, Plonka PM, Slawinski J, et al. What’s the use of generating melanin? Exp Dermatol. 1999;8:153–64.
Article  CAS  PubMed  Google Scholar 
Burkhart CG, Burkhart CN. The mole theory: primary function of melanocytes and melanin may be antimicrobial defense and immunomodulation (not solar protection). Int J Dermatol. 2005;44:340–2.
Article  PubMed  Google Scholar 
Plonka PM, Passeron T, Brenner M, Tobin DJ, Shibahara S, Thomas A, et al. What are melanocytes really doing all day long…? Exp Dermatol. 2009;18:799–819.
Article  CAS  PubMed  Google Scholar 
JRC. 2020 Cancer incidence and mortality in EU-27 countries. 2020. https://ec.europa.eu/jrc/en/news/2020-cancer-incidence-and-mortality-eu-27-countries. Accessed 15 Oct 2021.
Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol. 2012;5:739–53.
PubMed  PubMed Central  Google Scholar 
Shields CL, Shields JA, Gunduz K, Cater J, Mercado GV, Gross N, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118:1497–507.
Article  CAS  PubMed  Google Scholar 
Mundra PA, Dhomen N, Rodrigues M, Mikkelsen LH, Cassoux N, Brooks K, et al. Ultraviolet radiation drives mutations in a subset of mucosal melanomas. Nat Commun. 2021;12:259.
Article  CAS  PubMed  PubMed Central  Google Scholar 
Mikkelsen LH. Molecular biology in conjunctival melanoma and the relationship to mucosal melanoma. Acta Ophthalmol. 2020;98(Suppl 115):1–27.
Article  PubMed  Google Scholar 
Shields CL, Lally SE, Orloff M. Controlling conjunctival melanoma—to infinity and beyond. JAMA Ophthalmol. 2020;138:608–9.
Article  PubMed  Google Scholar 
Gardrat S, Houy A, Brooks K, Cassoux N, Barnhill R, Dayot S, et al. Definition of biologically distinct groups ofconjunctival melanomas according to etiological factors and implications for precision medicine. Cancers. 2021;13:3836.
Virgili G, Parravano M, Gatta G, Capocaccia R, Mazzini C, Mallone S, et al. Incidence and survival of patients with conjunctival melanoma in Europe. JAMA Ophthalmol. 2020;138:601–8.
Article  PubMed  PubMed Central  Google Scholar 
Gaudy-Marqueste C, Macagno N, Loundou A, Pellegrino E, Ouafik L, Budden T, et al. Molecular characterization of fast-growing melanomas. J Am Acad Dermatol. 2021. https://doi.org/10.1016/j.jaad.2021.07.011.
Rivolta C, Royer-Bertrand B, Rimoldi D, Schalenbourg A, Zografos L, Leyvraz S, et al. UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation. J Hum Genet. 2016;61:361–2.
Article  CAS  PubMed  Google Scholar 
Pacheco RR, Yaghy A, Dalvin LA, Vaidya S, Perez AL, Lally SE, et al. Conjunctival melanoma: outcomes based on tumour origin in 629 patients at a single ocular oncology centre. Eye (Lond). 2021. https://doi.org/10.1038/s41433-021-01508-y.
Triay E, Bergman L, Nilsson B, All-Ericsson C, Seregard S. Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol. 2009;93:1524–8.
Article  CAS  PubMed  Google Scholar 
Seregard S. Conjunctival melanoma. Surv Ophthalmol. 1998;42:321–50.
Article  CAS  PubMed  Google Scholar 
Jain P, Finger PT, Fili M, Damato B, Coupland SE, Heimann H, et al. Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study. Br J Ophthalmol. 2021;105:1358–64.
Article  PubMed  Google Scholar 
Tuomaala S, Eskelin S, Tarkkanen A, Kivela T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43:3399–408.
PubMed  Google Scholar 
Shields CL, Yaghy A, Dalvin LA, Vaidya S, Pacheco RR, Perez AL, et al. Conjunctival melanoma: outcomes based on the American Joint Committee on Cancer Clinical Classification (8th Edition) of 425 patients at a single ocular oncology center. Asia Pac J Ophthalmol (Philos). 2020;10:146–51.
Article  Google Scholar 
Cisarova K, Folcher M, El Zaoui I, Pescini-Gobert R, Peter VG, Royer-Bertrand B, et al. Genomic and transcriptomic landscape of conjunctival melanoma. PLoS Genet. 2020;16:e1009201.
Article  CAS  PubMed  PubMed Central  Google Scholar 
Sekulic A, Haluska P Jr., Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008;83:825–46.
Article  CAS  PubMed  Google Scholar 
Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10:3163.
Article  PubMed  PubMed Central  Google Scholar 
Worrall C, Suleymanova N, Crudden C, Trocoli Drakensjo I, Candrea E, Nedelcu D, et al. Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma. Oncogene. 2017;36:3274–86.
Article  CAS  PubMed  PubMed Central  Google Scholar 
Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, Dricu A, et al. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 2000;60:5278–83.
CAS  PubMed  Google Scholar 
Girnita L, Girnita A, Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA. 2003;100:8247–52.
Article  CAS  PubMed  PubMed Central  Google Scholar 
Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H. Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol. 2006;126:2490–506.
Article  CAS  PubMed  Google Scholar 
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362:857–60.
Article  CAS  PubMed  Google Scholar 
Seregard S. Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma. J Clin Pathol. 1996;49:338–42.
Article  CAS  PubMed  PubMed Central  Google Scholar 
Jay V, Ho M, Hunter W, Rootman D, Zielenska M. Expression of p53 in conjunctival melanocytic nevi. An immunohistochemical study. Arch Pathol Lab Med. 1996;120:378–9.
CAS  PubMed  Google Scholar 
Keijser S, Maat W, Missotten GS, de Keizer RJ. A new cell line from a recurrent conjunctival melanoma. Br J Ophthalmol. 2007;91:1566–7.
Article  PubMed  PubMed Central  Google Scholar 
Nareyeck G, Wuestemeyer H, von der Haar D, Anastassiou G. Establishment of two cell lines derived from conjunctival melanomas. Exp Eye Res. 2005;81:361–2.
Article  CAS  PubMed  Google Scholar 
Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1:1001–8.
CAS  PubMed  Google Scholar 
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–8.
Article  CAS  PubMed  Google Scholar 
Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z. Mdm2 association with p53 targets its ubiquitination. Oncogene. 1998;17:2543–7.
Article  CAS  PubMed  Google Scholar 
Froment P, Dupont J, Christophe-Marine J. Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival. Cell Cycle. 2008;7:3098–103.
Article  CAS  PubMed  Google Scholar 
Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, Lefkowitz RJ, et al. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem. 2005;280:24412–9.
Article  CAS  PubMed  Google Scholar 
Girnita L, Takahashi SI, Crudden C, Fukushima T, Worrall C, Furuta H, et al. Chapter seven—when phosphorylation encounters ubiquitination: a balanced perspective on IGF-1R signaling. Prog Mol Biol Transl Sci. 2016;141:277–311.
Article  CAS  PubMed  Google Scholar 
Suleymanova N, Crudden C, Worrall C, Dricu A, Girnita A, Girnita L. Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation. Oncotarget. 2017;8:82256–67.
Article  PubMed  PubMed Central  Google Scholar 
Yoshihara H, Fukushima T, Hakuno F, Saeki Y, Tanaka K, Ito A, et al. Insulin/insulin-like growth factor (IGF) stimulation abrogates an association between a deubiquitinating enzyme USP7 and insulin receptor substrates (IRSs) followed by proteasomal degradation of IRSs. Biochem Biophys Res Commun. 2012;423:122–7.
Article  CAS  PubMed  Google Scholar 
Girnita L, Worrall C, Takahashi S, Seregard S, Girnita A. Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci. 2014;71:2403–27.
Article  CAS  PubMed  Google Scholar 
de Waard NE, Cao J, McGuire SP, Kolovou PE, Jordanova ES, Ksander BR, et al. A murine model for metastatic conjunctival melanoma. Invest Ophthalmol Vis Sci. 2015;56:2325–33.
Article  PubMed  Google Scholar 
Crudden C, Girnita A, Girnita L. Targeting the IGF-1R: the tale of the tortoise and the hare. Front Endocrinol. 2015;6:64.
Article  Google Scholar 
Crudden C, Song D, Cismas S, Trocme E, Pasca S, Calin GA, et al. Below the surface: IGF-1R therapeutic targeting and its endocytic journey. Cells. 2019;8:1223.
Article  PubMed  PubMed Central  Google Scholar 
Suleymanova N, Crudden C, Shibano T, Worrall C, Oprea I, Tica A, et al. Functional antagonism of beta-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes. Oncogene. 2017;36:5734–44.
Article  CAS  PubMed  PubMed Central  Google Scholar 
Crudden C, Shibano T, Song D, Suleymanova N, Girnita A, Girnita L. Blurring boundaries: receptor tyrosine kinases as functional G protein-coupled receptors. Int Rev Cell Mol Biol. 2018;339:1–40.
Article  CAS  PubMed  Google Scholar 
Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene. 2008;27:1629–38.
Article  CAS  PubMed  Google Scholar 
Crudden C, Girnita L. The tale of a tail: the secret behind IGF-1R’s oncogenic power. Sci Signal. 2020;13:eabb7887.
Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A, et al. Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem. 2007;282:11329–38.
Article  CAS  PubMed  Google Scholar 
Fiorentzis M, Katopodis P, Kalirai H, Seitz B, Viestenz A, Coupland SE. Conjunctival melanoma and electrochemotherapy: preliminary results using 2D and 3D cell culture models in vitro. Acta Ophthalmol. 2019;97:e632–e40.
Article  CAS  PubMed  Google Scholar 
Maures T, Chan SJ, Xu B, Sun H, Ding J, Duan C. Structural, biochemical, and expression analysis of two distinct insulin-like growth factor I receptors and their ligands in zebrafish. Endocrinology. 2002;143:1858–71.
Article  CAS  PubMed  Google Scholar 
Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873–7.
Article  CAS  PubMed  Google Scholar 
Vasilcanu R, Vasilcanu D, Sehat B, Yin S, Girnita A, Axelson M, et al. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol Pharmacol. 2008;73:930–9.
Article  CAS  PubMed  Google Scholar 
All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 2002;43:1–8.
PubMed  Google Scholar 
Economou MA, All-Ericsson C, Bykov V, Girnita L, Bartolazzi A, Larsson O, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci. 2005;46:4372–5.
Article  PubMed  Google Scholar 
Vasilcanu D, Weng WH, Girnita A, Lui WO, Vasilcanu R, Axelson M, et al. The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene. 2006;25:3186–95.
Article  CAS  PubMed  Google Scholar 
Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, Girnita A, et al. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:2337–42.
Article  PubMed  Google Scholar 
Kanter-Lewensohn L, Dricu A, Wang M, Wejde J, Kiessling R, Larsson O. Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Melanoma Res. 1998;8:389–97.
Article  CAS  PubMed  Google Scholar 
Crudden C, Shibano T, Song D, Dragomir MP, Cismas S, Serly J, et al. Inhibition of G protein-coupled receptor kinase 2 promotes unbiased downregulation of IGF1 receptor and restrains malignant cell growth. Cancer Res. 2021;81:501–14.
Article  CAS  PubMed  Google Scholar 
Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, et al. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature. 2011;477:349–53.
Article  CAS  PubMed  PubMed Central  Google Scholar 
Crudden C, Ilic M, Suleymanova N, Worrall C, Girnita A, Girnita L. The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment? Growth Horm IGF Res. 2015;25:2–12.
Article  CAS  PubMed  Google Scholar 
Kohout TA, Lin FS, Perry SJ, Conner DA, Lefkowitz RJ. beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci USA. 2001;98:1601–6.
CAS  PubMed  PubMed Central  Google Scholar 
Sehat B, Andersson S, Girnita L, Larsson O. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res. 2008;68:5669–77.
Article  CAS  PubMed  Google Scholar 
Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.
Article  PubMed  PubMed Central  Google Scholar 
Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010;28:2174–80.
Article  PubMed  PubMed Central  Google Scholar 
Ren J, Liu S, Cui C, Ten Dijke P. Invasive behavior of human breast cancer cells in embryonic zebrafish. J Vis Exp. 2017:55459.
Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4:303–6.
Article  PubMed  PubMed Central  Google Scholar 
Download references
We gratefully acknowledge Prof. Robert J Lefkowitz, Prof. Gerasimos Anastassiou, Prof. Rob J W de Keizer, Prof. Rolf Kiessling, and Prof. A. Ciechanover for providing cell lines and reagents. We thank Anna Malmerfelt at the histology core facility, Karolinska Institutet, for technical assistance. Research support was received from the Swedish Research Council, Swedish Cancer Society, The Swedish Childhood Cancer Foundation, Crown Princess Margareta’s Foundation for the Visually Impaired, Welander Finsen Foundation, King Gustaf V Jubilee Foundation, China Scholarship Council (Grant no. 201700260284), Stockholm Cancer Society, Stockholm County and Karolinska Institute. Schematics were partially created with BioRender.com.
Department of Oncology and Pathology, BioClinicum, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
Dawei Song, Sonia Cismas, Caitrin Crudden, Eric Trocme, Claire Worrall, Naida Suleymanova, Tingting Lin, Huiyuan Zheng, Ada Girnita & Leonard Girnita
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117, Amsterdam, The Netherlands
Caitrin Crudden
Ophthalmic Pathology and Oncology Service, St. Erik Eye Hospital, Stockholm, Sweden
Eric Trocme, Stefan Seregard & Leonard Girnita
Tianjin International Joint Research and Development Centre of Ophthalmology and Vision Science, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China
Tingting Lin
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Huiyuan Zheng
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Stefan Seregard
Skin Cancer Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
Ada Girnita
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
Experimental design: DS, SC, CC, ET, CW, NS, TL, HZ, SS, AG, and LG. Development of methodology: DS, SC, CC, CW, and LG. Acquisition of data: DS, SC, CC, ET, CW, NS, TL, and HZ. Data curation and validation: DS, SC, CC, ET, CW, and LG. Analysis and interpretation of data: DS, SC, CC, ET, CW, NS, TL, HZ, SS, AG, and LG. Writing, review, and/or revision of the manuscript: DS, SC, CC, ET, CW, NS, SS, AG, and LG. Administrative, technical, or material support: DS, SC, CC, CW, SS, AG, and LG. Concept, project design, and study supervision: LG. All authors reviewed and approved the final manuscript.
Correspondence to Leonard Girnita.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
Song, D., Cismas, S., Crudden, C. et al. IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma. Oncogene 41, 600–611 (2022). https://doi.org/10.1038/s41388-021-02111-x
Download citation
Received: 23 August 2021
Revised: 27 September 2021
Accepted: 29 October 2021
Published: 17 November 2021
Issue Date: 21 January 2022
DOI: https://doi.org/10.1038/s41388-021-02111-x
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative
Cell Death & Disease (2023)

Advertisement
Oncogene (Oncogene) ISSN 1476-5594 (online) ISSN 0950-9232 (print)
© 2024 Springer Nature Limited

source

About The Author

admin

See author's posts